• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ProEx C 在肿瘤性和非肿瘤性尿路上皮病变的组织学评估中的应用。

Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.

机构信息

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095.

出版信息

Hum Pathol. 2013 Nov;44(11):2509-17. doi: 10.1016/j.humpath.2013.06.011. Epub 2013 Sep 9.

DOI:10.1016/j.humpath.2013.06.011
PMID:24029711
Abstract

ProEx C is an antibody cocktail targeting the expression of topoisomerase IIα and minichromosome maintenance protein 2. ProEx C staining is being used mainly to assist in diagnoses of dysplasia in gynecological specimens. This study was designed to determine the utility of ProEx C in assessing the urothelial lesions. Sixty-four patient specimens were divided into 5 groups: group I, 22 benign; group II, 13 low-grade noninvasive papillary urothelial carcinoma; group III, 10 high-grade urothelial carcinoma in situ (flat lesion); and group IV, 19 high-grade noninvasive papillary and invasive urothelial carcinomas. ProEx C reactions were scored in basal, parabasal, intermediate, and superficial cell layers. A sample was recorded as positive when nuclear staining was seen in the cells of the intermediate and/or superficial layers. Of 22 cases in group I, 21 were negative for ProEx C with a specificity of 95%. Of 13 cases in group II, 11 had positive results with sensitivity of 85%. All cases in groups III and IV had positive staining pattern with ProEx C with a sensitivity of 100%. In this study, ProEx C stain had an overall 95% sensitivity and specificity with positive and negative predictive values of 98% and 91%, respectively, for detection of urothelial carcinoma. We conclude that ProEx C is effective in differentiating carcinoma in situ and benign urothelial lesions. It also resolves issues in low- versus high-grade papillary urothelial carcinomas. To our knowledge, this is the first publication on the diagnostic application of ProEx C in histopathology of the urothelial lesions.

摘要

ProEx C 是一种针对拓扑异构酶 IIα 和微小染色体维持蛋白 2 表达的抗体鸡尾酒。ProEx C 染色主要用于辅助诊断妇科标本中的发育不良。本研究旨在确定 ProEx C 在评估尿路上皮病变中的效用。64 例患者标本分为 5 组:I 组 22 例良性;II 组 13 例低级别非浸润性乳头状尿路上皮癌;III 组 10 例高级别原位尿路上皮癌(扁平病变);IV 组 19 例高级别非浸润性乳头状和浸润性尿路上皮癌。ProEx C 反应在基底、副基底、中间和浅层细胞层中进行评分。当中间和/或浅层细胞中的细胞核染色可见时,将样本记录为阳性。I 组 22 例中,21 例 ProEx C 阴性,特异性为 95%。II 组 13 例中,11 例阳性,敏感性为 85%。III 组和 IV 组所有病例的 ProEx C 染色均呈阳性,敏感性为 100%。在这项研究中,ProEx C 染色对检测尿路上皮癌的总体敏感性和特异性分别为 95%和 91%,阳性和阴性预测值分别为 98%和 91%。我们得出结论,ProEx C 可有效区分原位癌和良性尿路上皮病变。它还解决了低级别与高级别乳头状尿路上皮癌之间的问题。据我们所知,这是 ProEx C 在尿路上皮病变组织病理学诊断应用方面的首次报道。

相似文献

1
Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.ProEx C 在肿瘤性和非肿瘤性尿路上皮病变的组织学评估中的应用。
Hum Pathol. 2013 Nov;44(11):2509-17. doi: 10.1016/j.humpath.2013.06.011. Epub 2013 Sep 9.
2
ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.ProEx C 作为一种辅助标志物,可提高尿液标本中尿路上皮癌的细胞学检测。
Cancer Cytopathol. 2013 Jun;121(6):320-8. doi: 10.1002/cncy.21264. Epub 2013 Jan 30.
3
Expression of ProEx C in primary and metastatic urothelial carcinoma.ProEx C在原发性和转移性尿路上皮癌中的表达。
Diagn Cytopathol. 2015 Mar;43(3):181-7. doi: 10.1002/dc.23193. Epub 2014 Jun 28.
4
Comparative evaluation of ProEx C and ImmunoCyt/uCyt assays in atypical urine cytology.ProEx C与免疫细胞/u细胞检测法在非典型尿液细胞学中的比较评估
Arch Pathol Lab Med. 2014 Sep;138(9):1215-22. doi: 10.5858/arpa.2013-0433-OA.
5
Significance of denuded urothelium in papillary urothelial lesions.乳头型尿路上皮病变中裸露尿路上皮的意义。
Am J Surg Pathol. 2007 Feb;31(2):298-303. doi: 10.1097/01.pas.0000213333.02240.d0.
6
Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.膀胱活检标本中残留肿瘤细胞的检测:细胞角蛋白染色解读中的陷阱。
Am J Surg Pathol. 2007 Mar;31(3):390-7. doi: 10.1097/01.pas.0000213367.41251.5d.
7
Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.p16INK4a、微小染色体维持蛋白2、DNA拓扑异构酶IIα、ProEX C以及p16INK4a/ProEX C在宫颈鳞状上皮内病变中的评估
Hum Pathol. 2007 Sep;38(9):1335-44. doi: 10.1016/j.humpath.2007.01.025. Epub 2007 May 18.
8
Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.成纤维细胞生长因子受体3的强免疫组化表达、细胞角蛋白20的浅表染色模式以及低增殖活性可确定那些不会复发的低恶性潜能乳头状尿路上皮肿瘤。
Cancer. 2008 Feb 1;112(3):636-44. doi: 10.1002/cncr.23212.
9
Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.经尿道切除术后 T1 期膀胱尿路上皮癌的亚分期对预后的意义。
Am J Surg Pathol. 2012 Mar;36(3):454-61. doi: 10.1097/PAS.0b013e31823dafd3.
10
Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.多色荧光原位杂交(UroVysion)在扁平尿路上皮病变鉴别诊断中的价值
J Clin Pathol. 2008 Mar;61(3):272-7. doi: 10.1136/jcp.2007.049684. Epub 2007 Aug 10.

引用本文的文献

1
p16 is superior to Stathmin-1 and HSP27 in identifying cervical dysplasia.p16 在识别宫颈发育不良方面优于 Stathmin-1 和 HSP27。
Diagn Pathol. 2021 Sep 20;16(1):85. doi: 10.1186/s13000-021-01144-w.
2
ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.ProEx C作为尿液样本中尿路上皮癌检测的诊断标志物:综述
Int J Med Sci. 2017 Apr 21;14(6):554-559. doi: 10.7150/ijms.17890. eCollection 2017.
3
Comparative study of ProEx C immunocytochemistry and UroVysion fluorescent in-situ hybridization assays on urine cytology specimens.
尿液细胞学标本中ProEx C免疫细胞化学与UroVysion荧光原位杂交检测的对比研究
Cytojournal. 2015 Jan 22;12:2. doi: 10.4103/1742-6413.149845. eCollection 2015.